BERLIN--(Marketwire - September 19, 2011) -
MagForce Nanotechnologies AG /
MagForce AG Completes Share Placement
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Announcement in accordance with section 17 para. 2 of the General Terms and
Conditions of Deutsche Börse AG for the Regulated Unofficial Market on
Frankfurt Stock Exchange
MagForce AG (FSE: MF6), a leading medical technology
company focusing on nanomedicine in oncology, has completed a share
from its authorized capital. In connection with the transaction, the
nominal capital increased from EUR 4,070,681, divided into 4,070,681 no par
value common shares in bearer form with an imputed nominal value of EUR
EUR 56,360.00 to EUR 4,127,041.00. Dr. Peter Heinrich, CEO of MagForce AG,
with international investors participated in the share placement. The
excluded subscription rights to existing shareholders by its authority
sec. 6 para. 4 of its articles of incorporation (Satzung).
A total of 56,360.00 new common bearer shares with profit participation
dating from January 1, 2011 were issued in the private placement at a price
EUR 12.42 per share. The gross proceeds of the capital increase in the
approx. EUR 700,000.00 will go to the company and will be used to finance
MagForce AG is a leading medical technology company focusing on
oncology. The company's proprietary procedure, NanoTherm® therapy,
targeted treatment of solid tumors through the intratumoral release of heat
magnetic nanoparticles. NanoTherm(®), NanoPlan(®), and
components of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce, NanoTherm,
and NanoActivator are trademarks of MagForce AG in selected countries.
This release may contain forward-looking statements and information which
identified by formulations using terms such as "expects", "aims",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such
forward-looking statements are based on our current expectations and
which may be subject to a variety of risks and uncertainties. The results
actually achieved by MagForce Nanotechnologies AG may substantially differ
these forward-looking statements. MagForce Nanotechnologies AG assumes no
obligation to update these forward-looking statements or to correct them in
of developments which differ from those anticipated.
--- End of Message ---
MagForce Nanotechnologies AG
Max-Dohrn-Str. 8 Berlin Germany
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce Nanotechnologies AG via Thomson Reuters ONE